<SEC-DOCUMENT>0001564590-19-036823.txt : 20191011
<SEC-HEADER>0001564590-19-036823.hdr.sgml : 20191011
<ACCEPTANCE-DATETIME>20191011114921
ACCESSION NUMBER:		0001564590-19-036823
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20191011
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191011
DATE AS OF CHANGE:		20191011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		191147514

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-8k_20191011.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-11T10:36:21.9152768+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : d6614e9632594a01a256850d8f4b16f2 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fgen="http://www.fibrogen.com/20191011" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fgen-8k_20191011.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000921299_20191011_20191011">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000921299_20191011_20191011">FIBROGEN INC</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000921299_20191011_20191011">0000921299</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fgen-20191011.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000921299_20191011_20191011">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-11</xbrli:startDate>
					<xbrli:endDate>2019-10-11</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000921299_20191011_20191011">8-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000921299_20191011_20191011" format="ixt:datemonthdayyearen">October 11, 2019</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.67%;"></td>
<td style="width:0.83%;"></td>
<td style="width:34.51%;"></td>
<td style="width:0.99%;"></td>
<td style="width:32%;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000921299_20191011_20191011" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000921299_20191011_20191011">001-36740</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000921299_20191011_20191011">77-0357827</ix:nonNumeric></p></td>
</tr>
<tr style="height:20.9pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000921299_20191011_20191011">409 Illinois Street</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000921299_20191011_20191011">San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000921299_20191011_20191011">CA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000921299_20191011_20191011">94158</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000921299_20191011_20191011">415</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000921299_20191011_20191011">978-1200</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report.)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000921299_20191011_20191011" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000921299_20191011_20191011" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000921299_20191011_20191011" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000921299_20191011_20191011" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:35%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="bottom" style="width:35%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:35%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000921299_20191011_20191011">Common Stock, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style="width:30%; border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000921299_20191011_20191011">FGEN</ix:nonNumeric></p></td>
<td valign="top" style="width:35%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000921299_20191011_20191011" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.33%;text-indent:-23.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000921299_20191011_20191011" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:2pt;border-bottom:Double 2.25pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"><tr><td></td></tr></table></div>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_1"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.01</span></p></td>
<td valign="bottom" style="width:91%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulation FD Disclosure</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2019, FibroGen, Inc. (FibroGen) issued a press release announcing that results from the global <span style="color:#000000;">Phase 3 </span>roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2019 (ASN), taking place from November 5-10 in Washington D.C. <span style="color:#000000;">A total of nine presentations of roxadustat clinical results (one late-breaker oral presentation, three additional oral presentations, and five poster presentations) will be presented by FibroGen, or its collaboration partners AstraZeneca and Astellas Pharma, Inc., at this year&#8217;s meeting.</span> A copy of such press release, which includes a link to the ASN website containing t<span style="color:#000000;">he accepted abstracts of the individual Phase 3 roxadustat studies,</span> is attached&#160;as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.28%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Item&#160;7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in Item&#160;7.01 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_2">Item&#160;9.01</p></td>
<td valign="bottom" style="width:91%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.18%;"></td>
<td style="width:5.6%;"></td>
<td style="width:1.11%;"></td>
<td style="width:50.47%;"></td>
<td style="width:40.64%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex991_6.htm"><span style="text-decoration:underline;">Press Release titled &#8220;Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019&#8221; dated October 11, 2019</span></a></p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_3"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</span></p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:47.78%;"></td>
<td style="width:1.11%;"></td>
<td style="width:1.64%;"></td>
<td style="width:0.37%;"></td>
<td style="width:2.86%;"></td>
<td style="width:1.63%;"></td>
<td style="width:44.61%;"></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F<span style="font-size:9pt;">IBRO</span>G<span style="font-size:9pt;">EN</span>, I<span style="font-size:9pt;">NC</span>.</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: October 11, 2019</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.45pt;">
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Lowenstein</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Lowenstein</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fgen-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="geapbbklwiq5000001.jpg" title="" alt="" style="width:287px;height:78px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pooled efficacy and cardiovascular safety of roxadustat, compared<br /> to epoetin alfa (EPO) in CKD patients on dialysis and compared to placebo in CKD patients not on dialysis, to be presented as late-breaker</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAN FRANCISCO, October 11, 2019 - FibroGen, Inc. (NASDAQ: FGEN), today announced that results from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2019 taking place from November 5-10 in Washington D.C. A total of nine presentations of roxadustat clinical results (one late-breaker oral presentation, three additional oral presentations, and five poster presentations) will be presented by FibroGen, or its collaboration partners AstraZeneca and Astellas Pharma, Inc., at this year&#8217;s meeting.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accepted abstracts on the individual Phase 3 roxadustat studies are now available on the ASN website at <font style="font-style:italic;text-decoration:underline;color:#0000FF;">https://www.asn-online.org/education/kidneyweek/2019/program-annual.aspx</font><font style="font-style:italic;color:#1F497D;font-family:Calibri;"> </font> </p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presentation data include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Primary efficacy endpoint met in each of the three placebo-controlled Phase 3 studies (OLYMPUS, ANDES, ALPS) in patients with CKD anemia not on dialysis </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Primary efficacy endpoint met comparing roxadustat to erythropoiesis-stimulating agents (ESAs) in CKD patients with anemia on dialysis (ROCKIES, HIMALAYAS, SIERRAS, and PYRENEES): </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:11pt;"><font style="font-family:Times New Roman;">Significant reduction in red blood cell transfusion is demonstrated in roxadustat-treated patients compared with epoetin alfa in SIERRAS</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:11pt;"><font style="font-family:Times New Roman;">In subgroup analysis of patients with inflammation (increased C-reactive protein levels), roxadustat-treated patients achieved statistically larger increase in hemoglobin level from baseline than epoetin alfa-treated patients in ROCKIES</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Times New Roman;">Confirmed global Phase 3 pooled efficacy and cardiovascular safety results to be presented at late-breaker session on Friday, November 8, at 2pm</font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"We are excited to present results from our global Phase 3 studies, including the pooled cardiovascular safety results,&#8221; said Dr. K. Peony Yu, M.D., Chief Medical Officer, FibroGen. &#8220;We believe roxadustat, a first-in-class oral treatment for anemia, may provide an efficacious and well-tolerated treatment option to physicians and to their patients suffering from CKD anemia.&#8221;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Key roxadustat oral and poster presentations at ASN Kidney Week 2019:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:18.93%;"></td>
<td style="width:60.19%;"></td>
<td style="width:20.77%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead Author</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abstract / Presentation Title</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-right:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date / Time</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provenzano </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIMALAYAS: A Phase 3, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Incident-Dialysis Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen-sponsored</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oral Presentation </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TH-OR021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 7, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4:30-4:42PM</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fishbane</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROCKIES: An International, Phase 3, Randomized, Open-Label, Active-Controlled Study of Roxadustat for Anemia in Dialysis-Dependent CKD Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">AstraZeneca-sponsored</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oral Presentation </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TH-OR022</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 7, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4:42-4:54 PM</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fishbane</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLYMPUS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study of Roxadustat for Anemia in Patients with Non-Dialysis-Dependent (NDD) Chronic Kidney Disease (CKD)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">AstraZeneca-sponsored</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oral Presentation </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TH-OR023</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 7, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4:54-5:06 PM</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charytan</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SIERRAS: A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in Subjects with End Stage Renal Disease (ESRD) on Stable Dialysis</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen-sponsored</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poster</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SA-PO227</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 9, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10:00 AM-12:00 PM</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coyne</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANDES: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen-sponsored</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poster</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SA-PO228</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 9, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10:00 AM-12:00 PM</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Esposito</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two Phase 3, Multicenter, Randomized, Studies of Intermittent Oral Roxadustat in Anemic CKD Patients on (PYRENEES) and Not on (ALPS) Dialysis </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Astellas-sponsored</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poster</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SA-PO225</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 9, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10:00 AM-12:00 PM </p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Akizawa</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3, Multicenter, Randomized, Open-Label, Non-Comparative Study of Intermittent Oral Roxadustat in ESA-Naive CKD Patients Not on Dialysis in Japan </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Astellas-sponsored</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #999999; border-right:solid 0.75pt #999999; border-top:solid 0.75pt #999999; border-left:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poster</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SA-PO226</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 9, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10:00 AM-12:00 PM</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Barranco </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An Open-Label Extension Study to Evaluate the Efficacy and Safety of Roxadustat for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients with Chronic Kidney Disease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen-sponsored</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #999999; border-bottom:solid 0.75pt #999999; border-left:solid 0.75pt #999999; border-right:solid 0.75pt #999999;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poster</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SA-PO230</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov 9, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10:00 AM-12:00 PM</p></td>
</tr>
</table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is approved by the National Medical Products Administration (NMPA) in China for the treatment of anemia in CKD patients on dialysis and not on dialysis, and by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for the treatment of anemia in CKD patients on dialysis. Submission of the U.S. New Drug Application (NDA) is expected in Q4 2019, with the European Marketing Authorization Application (MAA) submission to follow.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Anemia Associated with Chronic Kidney Disease (CKD)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia can be a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin, a protein in red blood cells that carries oxygen to cells throughout the body. Anemia in CKD is associated with increased risk of hospitalization, cardiovascular complications and death, also frequently causing significant fatigue, cognitive dysfunction and reduced quality of life.&nbsp;&nbsp;Severe anemia is common in patients with CKD, cancer, myelodysplastic syndromes (MDS), inflammatory diseases, and other serious illnesses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia is particularly prevalent in patients with CKD.&nbsp;&nbsp;The prevalence of CKD in the adult population is estimated at 10-12% globally, and is generally a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure, or end stage renal disease, requiring dialysis or kidney transplant to survive. Blood transfusion is used for treating life-threatening severe anemia. However, blood transfusions reduce the patient&#8217;s opportunity for kidney transplant, increase risk of infections and the risk of complications such as heart failure and allergic reactions.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the United States Renal Data System (USRDS), over 14% of the U.S. adult population is affected by CKD, and a majority of dialysis-eligible CKD patients are currently on dialysis. It is estimated that approximately 507,000 patients are receiving dialysis in the U.S. as of 2016. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Roxadustat</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat (FG-4592) is a first-in-class, orally administered small molecule HIF-PH inhibitor that promotes erythropoiesis through increasing endogenous production of erythropoietin, improving iron regulation, and overcoming the negative impact of inflammation on hemoglobin syntheses and red blood cell production by downregulating hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis, increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of chronic kidney disease (CKD) patients, including in the presence of inflammation and without a need for supplemental intravenous iron. Roxadustat is currently approved in China for the treatment of anemia in CKD patients on dialysis and patients not on dialysis and approved in Japan for the treatment of anemia in CKD patients on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in the U.S., China, and other markets in the Americas and in Australia/New Zealand as well as Southeast Asia.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About FibroGen</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#8217;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH) activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), is approved by the National Medical Products Administration (NMPA) in China for CKD patients on dialysis and not on dialysis and by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for CKD patients on dialysis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit <font style="text-decoration:underline;color:#0000FF;">www.fibrogen.com</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of roxadustat, our interpretation of the pooled safety analyses and other analyses of the global Phase 3 program for roxadustat, the expected endpoints and potential standards for safety assessments of such data by the FDA and the EMA, the potential for and timing of an NDA submission to the FDA and an MAA submission to the EMA for potential marketing approval for roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;will&#8221;, &#8220;should,&#8221; &#8220;on track,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contact: <font style="font-weight:normal;"><br />FibroGen, Inc.&#160;<br />Investor Relations<br />1.415.978.1433<br /></font><font style="text-decoration:underline;color:#0000FF;font-weight:normal;">ir@fibrogen.com</font></p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geapbbklwiq5000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geapbbklwiq5000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ 2 # 2(  A$! Q$!_\0
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M/(7*C;VS5_Q+HT?A[X0WVE0S/-';V^T.X )S)GG'UK&^"/\ R#-8_P"OA/\
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M,4M[;HX]00F17O\ T&!2E+E2L@2NV>'>$_'>N>'O$::/XAFGEMVE$,JW)S)
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I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>fgen-20191011.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-11T10:36:21.9152768+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : d6614e9632594a01a256850d8f4b16f2 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:fgen="http://www.fibrogen.com/20191011" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.fibrogen.com/20191011" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.fibrogen.com/20191011/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20191011_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20191011_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fgen_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>fgen-20191011_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-11T10:36:21.9152768+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : d6614e9632594a01a256850d8f4b16f2 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="fgen-20191011.xsd#fgen_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="fgen_DocumentAndEntityInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and entity information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="fgen_DocumentAndEntityInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>fgen-20191011_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-11T10:36:21.9152768+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : d6614e9632594a01a256850d8f4b16f2 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fibrogen.com/20191011/role/TemplateLink" xlink:href="fgen-20191011.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20191011.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="fgen-20191011.xsd#fgen_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="fgen_DocumentAndEntityInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>fgen-8k_20191011_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20191011.xsd" xlink:type="simple"/>
    <context id="C_0000921299_20191011_20191011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2019-10-11</startDate>
            <endDate>2019-10-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000921299_20191011_20191011" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="C_0000921299_20191011_20191011" id="F_000003">FIBROGEN INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0000921299_20191011_20191011" id="F_000004">0000921299</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000921299_20191011_20191011" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000921299_20191011_20191011" id="F_000002">2019-10-11</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000921299_20191011_20191011" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000921299_20191011_20191011" id="F_000006">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000921299_20191011_20191011" id="F_000008">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000921299_20191011_20191011" id="F_000009">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000921299_20191011_20191011" id="F_000010">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000921299_20191011_20191011" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000921299_20191011_20191011" id="F_000012">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000921299_20191011_20191011" id="F_000013">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000921299_20191011_20191011" id="F_000014">978-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000921299_20191011_20191011" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000921299_20191011_20191011" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000921299_20191011_20191011" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000921299_20191011_20191011" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000921299_20191011_20191011" id="F_000019">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000921299_20191011_20191011" id="F_000020">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000921299_20191011_20191011" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000921299_20191011_20191011" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_RNPJXS=F__L?%%L*GAUUTT7U!+ P04    "  J7DM/F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( "I>2T^=DA&QH0(  ),+   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&ULC5;MCILP$'P5Q ,<V)!/$:3FJJJ56BFZJM??3N($=("I[237
MMZ]M.(2\:ZE_P#8S.VO6 UL\A'Q3%><Z>F^;3NWB2NM^FR3J5/&6J2?1\\X\
MN0C9,FVF\IJH7G)V=J2V26B:+I.6U5U<%F[M(,M"W'13=_P@(W5K6R;_[GDC
M'KN8Q!\++_6UTG8A*8N>7?E/KG_U!VEFR13E7+>\4[7H(LDON_@3V>YI;@D.
M\5KSAYJ-([N5HQ!O=O+MO(M3FQ%O^$G;$,S<[OR9-XV-9/+X,P:-)TU+G(\_
MHG]QFS>;.3+%GT7SNS[K:A>OX^C,+^S6Z!?Q^,K'#2WB:-S]=W[GC8';3(S&
M233*7:/336G1CE%,*BU['^YUY^Z/X4F>CS2<0$<"G0B9TTD&(9?Y9Z9964CQ
MB.3P\GMF:TRVU+R;DUUTK\(],\DKLWHOTR*YVS C8C\@Z Q!)D1B8D\"%!6@
MCI[-Z!2G9R@]<_1\1L^\_" BQP5R5" '](4G !%+7&"!"BP ?>4)0,0:%UBB
M DM WW@"$$%27&&%*JP@GW@2""10YS4JL89\O] 0$JC#!E780(7<4T @"UR"
MI+B;4AAAZ?L)P:P"*@'/$AAA[:L@F$U !3<NH2 "!=\&!!/X.A#<WP3:EU)?
M!<%D 17<Y 1ZF/K%QS"AZN-.)]#(%%0?P82JC]N=0#=34'T$$ZH^;GD"#9V!
MZB.84/5QUQ/HZ0Q4_[]]3W#C$VCKS/^V()B ",6=3Z&K,_^$(9B0"&Y\"DV=
M^7\K!!,2"?RPH:<S_Q1CF, IIKCO*?)C]T\QA@F<8HK[GD)/Y_XIQC#^*4YF
M[91M5W\P>:T[%1V%-IV9ZY\N0FANXJ5/QN&5Z9"G2<,OV@Y79BR'-G&8:-&/
M+7 R]>'E/U!+ P04    "  J7DM/,D7IE5<"   ;!@  %    'AL+W-H87)E
M9%-T<FEN9W,N>&ULA57;;MI $'U.OV*$^@BQ34B BB"Y7"(K"=" 5*E5'Y;U
M@%>U=]W==8"_[Q@2*GEQXR=[+F?/F9T9#XRQL,]2:>X;B;7Y%\\S/,&,F6N5
MHR3/1NF,6?K46\_D&EEL$D2;I5[;]^^\C G9@$**/P6.5"'M?:/3;@P'1@P'
M=CA6O,A06F RAHFTPAX@DB=(H>3 L\.!5X:>PN?<7D,0-*'M!_VJ\XP57L2"
MG^':6,VX_56;N3KD6'7V6H]54TC!\3%AFK)MU;MAJ7%0SD<L4 M5\HMAS*P3
M]Z[PT]75)8UOLEYP*THMA#=CF0,RC;Z^S!\F,XAFHQJ$$7'1+*4"Q;B'1SQ4
MXWQZ^NV@W:_C,,E0;X7<PH-6.YO 2&4YDP[.6_14I BS(ENC=D\*6C=WW8Y?
MDQI)KG2N]/$6F["T5#90&H[=I$F*BMUR3VK 5FP/44SBQ4;P4U]<9M7MMOR;
MVVZOW:U!"N-8HS'-]Q=X$A)A+ATN';\/49H*J80A]IJ&XR/(4?E%$E=JY\S
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M7PW_R?(+4$L! A0#%     @ *EY+3Q\CSP/     $P(   L
M ( !     %]R96QS+RYR96QS4$L! A0#%     @ *EY+3R?HAPZ"    L0
M !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  J7DM/FB#+9.X    K @  $0              @ &9 0  9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  J7DM/F5R<(Q &  "<)P  $P
M    @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "I>2T^=
MDA&QH0(  ),+   8              "  ?<(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  J7DM/,D7IE5<"   ;!@  %
M    @ '."P  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  J7DM/
MNJ$YBM<!   R!@  #0              @ %7#@  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( "I>2T\6;2-_0P$  #P"   /              "  5D0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  J7DM/_\ F"+T   "% @  &@
M            @ ')$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  J7DM/"X_8 R$!  !7!   $P              @ &^$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "@ * ( "   0%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-8k_20191011.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="fgen-8k_20191011.htm">fgen-8k_20191011.htm</File>
    <File>fgen-20191011.xsd</File>
    <File>fgen-20191011_lab.xml</File>
    <File>fgen-20191011_pre.xml</File>
    <File>fgen-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>11
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-8k_20191011.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fgen-8k_20191011.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20191011_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20191011_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20191011.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20191011",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20191011.htm",
      "contextRef": "C_0000921299_20191011_20191011",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20191011.htm",
      "contextRef": "C_0000921299_20191011_20191011",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "verboseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20191011/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "fgen_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and entity information.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.fibrogen.com/20191011",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>12
<FILENAME>0001564590-19-036823-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-19-036823-xbrl.zip
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MR/X<2/+&G;Q2WY\4W<+A=PI=_0]02P,$%     @ *EY+3V%4"14F!0  _RT
M !4   !F9V5N+3(P,3DQ,#$Q7W!R92YX;6SMFFUOXC@0Q]^?=-_!EWVSJ[N0
M!PI;4-D51]L3.MHBX.Y6]Z8*B0&KCHWL\/3M;QP((21IR>[FI)5"I0+)S/CO
M7\9C.^3F\]:G:(V%))QU-*MF:@@SEWN$S3O:2NJ.= G1D P<YCF4,]S1=EAJ
MGS_]_-/-+[J.;N_[CZCK!F2-;XET*9<K@=^/'SZ@+[^/!FA V,O4D1C=<G?E
M8Q8@'2V"8-DVC,UF4_-FA$E.5P&T+FLN]PVDZU'HGL"..H%NG0"C\-5&MFFU
M=,O4+6MBF>UZLVU;M9;5L#\VKW\US;9IG@3X>]\M=/)JHT;-A#_;O#XQ'#KN
MBS/'J'][8N@UF]85;C7K=J-UY9B68S>:UPW3NYY=3:WFS#Y5RI<[0>:+ +UW
M/X02H;^,84KQ#MT3YC"7.!2-HY[^AOK,K:$NI6BDW"0:88G%&GNU0U0*W-HT
M@@?7B,GP:T<[H;>="EKC8F[8IEDW(FOM8+Y-V6_JH;75:K6,\.S15)(L0PAK
M&5\>!F-W@7U'ATL%6>"J!B1IR_#@@+OA-;I %\JU4-_TR$Q7AW3+UNM6;2L]
M#6@@M.<A.,4C/$/J_:]1/]'FC$P%GV,6)I&Z I9I68:R-";87U)(H<&^QV&H
MA<"SCC8#!STR5JV]R[(-=DO(>DG@#/3=^"9!@;/EC/N[O;)H4$3O7>;=L8 $
MNSZ;<>&'9-]2/() ST4"Y7=G*2 +61!:*P )![P-,/.P%X51'2BGPZ&B2!/E
M;@* :E!"BV$&2>S6YGQM>)B$+:H/(1W=M [Y\PX./8^QNQ+0RMW673ALCA\=
M'R=Q4)7'7$0'J3/%M*/E^QK?7^1$.*KJCG?^E--+U9TYE2 KZK]E3R<DH(6Y
MQ7XEB!L*W.,^9)*+53KUI5QA,5%Y*IYF,RPN%?MVG/+%?[OLL@7#_$5<$D"^
M/4")%#"E79P,&9XE"/P'$@ZJE&*R8F0_,\E+->8XER!339ITN(#%U./*GUY^
MN=-^)8CKP9CMPLJKQ[V+QWK2IP11^TFBZWDP0\DAAW4(_9<LBTA\+4+9@L<P
MI>(G,11\3?;KI^*24S'*%JVNZ9.8\ W[*KVG[F5+/;S!D@5;7R4V&: TN1-G
MV_>@3I/9H;P4&_YO!"E--NQ5N%AR$;86YF&/KU@@=L7'WQNA2NO"/:$%:VW:
MKS1Q=SX6<Y@:_Q!\$RQ@_EDZ;%=,9TZ(TB3W( &%0_NPWMC^B0N*33F7)G.$
MYT1"6RPHLN+/]BU!9+0+&L**B,-&R%,W.BY5F>-<@LPN-..IINZI,[]4WIE3
MB?0FH*0HM+W/ZZ+26VUUY/FUK6MWJC+&#2Z14R!84N?I+KTKW$13CG"C9N!C
M:HN>O.URL#"6CH!XNKL@]+B[GPGN%])X4,&S.',!VY*.9IFF9=9,4T-+2%FU
M-^QHMH96$D3RI0JGM@70/=B_".P-]IQRY8?:83,A<6CY(V(Z&R0QIWK%*2N=
MSFI=S*M1\3KEE3V#Q;@^5KC2N%++DIA7J^*5YI6SYCQ2LZIBGT'M=$<1HZKJ
M?0:J-S:+,;VJ^F?0R[U/$'.KIH$,;IFWA&)FU520S^STGM^1F%U- _G$4G=U
M8VS5E)"/[>S^?0RMF@D2T)*_R\28JL*?P)3^72U&]=WK_1J+*?^!8>7\3'HD
M5J_J?8)7UD_?,:RJRB=@O?9 0PRMJO*O0<MX>"5&5U7^Y.!,/:04HZI6^@E4
M9T^:'3E=524L,Z62SPO&N/Z'$7ACI&C!/O9%/5>\/Z/^J6=M/_T'4$L#!!0
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M@R+LX59O"=@>8I1[+ON('CW6"_1SFH;PQ99PE,6R_/"A Q)XJY"@!FAW=B<
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MT=INCM-:R2I7MXC67E=V1?!"U_1( KKXB'J$W3-GC+GS\!KX.U,'J"![8_1
MDG_Q$<#39:O[J-\;0]];3'&I9$/<<V>2T?5I#$ALGL+VE]!Y*K'PFW"H=SV
M^3_%9JX=5O.6;69Z7#XD@<]R0?_V2]6V#H\4"9C'1@A XFL()JF; CX_.'FW
M1$#.1B,/%#?0S#XLXB_A%Y-1X$UJ[S4\TI#? <I[)$P9<(E",44\JN*0N;&+
MOZT4?UL]<6)KUM,8,.>GSAZAHY$4(//0 ]85]Z3+/'&'9(&%2#RDFO]*>MQ#
MM@!**,=T?1?()1! ,<.Q%U"?B;'R)D2!!:1Z$]TR:B"Z0"RA811EJR0BOV/H
M!TC1G\1E/>'!X-@.XRD<71RJ_EI!S^(GC'FN'D9,1R5+40^K(^%QZST#+Q$F
M.JPO&/F]23J3(7#.S'WR@HA9K'"4DPK''Y('0/KH?1O[D;6OGA<Z[ KA=2G0
M?  [#RFD=E@J':T8!0IA/X>H6N5M,+49KA6A &">Q $9)9+EVF/84"6['#&7
MN?PX3(O;LPY)X[)-[*)I0,4L9\W+;Q0$=K:$^! ;)14,19'O +S]_G<0*M")
M]VYVR0NC:3.[9 9_,HP0\'"+6"4*!E!BEZ121Z=[I&0:8<W=-GF!;9)*3+F6
M#&4)GM;2:?"H5<FK7F]-4W:W79Z)+L!#WDD@XC'I$N5AE]R\O=?=7VT'A75W
M>^@%]E!UR1YJ*C5F<K>3WM=.*K)\">_F6&4G1777BK"]6);L5CD=GNZ'>BL'
M6T+O#HU^)IF;(H+H9 NQ-">-G " \^?9_"6C7,I8]I+(_<:3D)<RC6+YUZ-H
M2GJ]*N%2(S&9QA4TGUA:(P+BTCKZPISL*IO(9W@KBKW!*R7"$T3.@#@>56H=
M[EXTUT#4*FAX')F?%5&2ZC!%J(RLA:-U-M,2Z+X,&C\RCEK141^]EU@LT8';
MWPTXO)F)A$RM^%'U-XG(E]E+SR&'-TT\>W-%9+$VGLIYB03^Q+*[FI.NF?(
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M:9P-/)_L.LA<D@JFM)G7K ^0:Z2%8-SW'4"[^@RDC<1T("_P?I40C"K=?K6
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M91!=CO[?UG8V?S;; '.\4[K_FC;#+KF_T:B]>5.X7[=O6837\X9NED8Z$Q7
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M8?@W*&&4-C$E:NBWF2F,5XI9WB233QZ8Y(QYOK DGP$=H.2!WV"-_W>&>,'
M#CHJ@%/9*1YY,O$4Y &\1:<1%24RY@N^*H$KIOK&RE1 ,J+Q0<B_3*5BDNT1
M'-R(RPH54()WF08_IR+.^@A73%QJY<P (@K]J'%?JKB4^+:%12/C_SR"'ODK
MG/B;CRR6L2WDAV[G*BQ9PVAZ@_VGZ#COD5/FF<8.T8ZA+\)V3OELA-ZN;N D
M!B+GUJP:A#\ R($FK0./O7)Z%T7"%B]$JR03B'W5&&3*G]P[^XA'^\;WNXAZ
MH;<!5N'^A5D2EU&D+BRL,EE33"U9IL 5S!I,)5\RC8QM%3)*W17=GC5&C@13
MMH0*RNE>[N<XC%K[TH<)LTR*;$V7.5PZ Z08#8A"K8-) ,K!I5U. H-9+'@%
MO8A.")XJ-FRUZP%CI0-_3&6NECKC&^S7,KA4>? 5G[LLZSS@JL[UP.;YFJ,?
M#9*Q+@^UN BRD/>I6_Q+996,!!OA&F("%2DO,*))MV@EHG(;TBQ4$-AI!8D9
M84J(+M U66UC+$Q]^,.NLV*0,,\DOKQIOM^E_F:0OS3]V<P[&:8+&XA@QJUQ
M@(XIV#*"$'>..J]J,S1#VD#K'"7K#=-HXT+S=G@:P:<\0UN\(E2:+ W)DHM$
M83QH'!<RD2DK%< RHN<+3UGU;654.8N<0_'K3@<'D+SQ>%PSI(#"U6"07/&I
MAU:FYUZ.# P8<^U7ORAU3@PSJ#8T)FBU?+-:OGF63N?6)?8VKRNQ]SCC/AM)
M6ERPQ@_(D_)1!AD:#0V<AB8S#=5BR&VBG*JE&DPC"(4.LI16!FC!P65@X!%H
M(T<II;2PH_G@LQ1F5LQ[:'.GCK5(IX%HH0JK*[MJRX2[3* --*>77(/Y.KNT
M\,1#XW3T'**=[D(!%V,E3;[<%!^D[[^0I\*CD8\96!R=CX$6H1,[0;S3K)[X
MM&K@X-I!ISU=<-D_:E?<-/(^+9[ ;6G2H0:/LF.T*6]A*?9$.V':BQY ]Z:_
M6>_A=,>,A:[NA?,S+TPQ)VRA%C$:#BAYB;$18ZY ^WQ]'O=R4%')4[ZTC&\$
MI.*(H))91X@7(Z%M2(7+2T30BA."B#XE'B%TA(\#D,S6]JT4G^4FQC8OL"]6
MYM0Z!$()#6NNB*2-OLST\\]Y_] 3RMX01J(XS*V;36)7(IX>,R65Y$#:D""S
M<Z,O3<V6T5PUWY!/IM6!W:6Q# )WJ9)?2T8J"_SY)XG%FGOG\]>]10];,9Z_
M2K28OT;0T),Q16=S=USAX2M=N\6F*YUKBC^NOC,7JZOCQN4H$_EE(FP";A+P
M0RCGD[0$E&4>CE@"!+U,-&R59^(JK;[ZDLH1&ZQ98R>0 3".UI#SHL^T7&R?
M8301 J!@I2E=;&43KH560FT6([U)+GV$ZE ^6DBUXI$1[B6+FE): %:6N^K3
M-F2VT_:GZ]]SJD]"2P;;+;"0I;I2AUI$=/K1-&57KF8=#56>W"B8&&NGIX#?
MP.ZDG)U+00NWNXD(ZHO$T[)OJ4"C:D<1D?%4T,*SJ2D.=T)+_9^G,<- )M3[
MA-8KR _ZB$8]6V]\LVGVT;Z=&8K?;+((M+_:Y6_S7;K,DNOUB&MHENMRAY%I
M\F>;!7L"P88TU#>QW:4W,@LEE&-UUG*]M[_W:IZL9BW<IEN@N\*$0K9++6C%
MZ#""_3 W33:59V0OA W4J4XVG4X%[I- @.O2I&#4S1)4<;O7X#?Y.1J079GZ
M+C*N]N^9QZZXRMW,Q"0I/R=;!1,'U,;SHMU9;%I2@NK:-UOQIDTB1@ZGO8M+
M3\0I#<)NB["6+>"T?=*$-@^[>_<A]P0_1F!#IY%!:%KLV@+*,[QHZHF7,Z>_
M_-1\W=BU=W()@T:X)3Q[O5G;:F[7=MZ\K36W-C?SJN26%_<)6A<.3NK_71#&
M7A\?V.\4[]Z+3P\1('SW^/!=G9(F%";61VD8X(__!U!+ 0(4 Q0    ( "I>
M2T]ZR3?A*04  &,8   1              "  0    !F9V5N+3(P,3DQ,#$Q
M+GAS9%!+ 0(4 Q0    ( "I>2T\VYW'P7@<  .=*   5              "
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2      4 !0!% 0  I3T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6645768624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 11, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 11,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
